Partial
Needs Revision
Patient Risk:
Low
Summary
The composition claim is supported by the supplied FDA label. The pricing and availability claims are not addressed by the label and require non-label evidence.
Category Scores
Accurate Statements
Maxitrol contains neomycin, polymyxin B, and dexamethasone.
The DESCRIPTION section identifies MAXITROL as containing neomycin sulfate equivalent to neomycin, polymyxin B sulfate, and dexamethasone.
Unsupported Statements
The price of Maxitrol depends on the country, pharmacy, and insurance coverage.
The supplied label contains no information about pricing, pharmacies, countries, or insurance coverage.
In many markets, products containing the same active ingredients as Maxitrol may be priced lower than the brand-name product.
The supplied label does not address comparative pricing, generic products, or market-specific costs.
Availability of products containing the same active ingredients as Maxitrol varies by country.
The supplied label does not discuss product availability, distribution, or country-specific access.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims concern commercial pricing and availability rather than dosing, administration, contraindications, warnings, or other direct safety information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Revision
Primary Issue
Three commercial claims are not supported or addressed by the supplied FDA-approved labeling.
Suggested Improvement
Retain the composition claim, but clearly identify pricing and availability statements as non-label information or remove them when evaluating alignment with the FDA label.